Skip to content

Study · Randomized controlled trial · n = 300 · 2025

4 results

Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Gu W, Lu Y, Ye X, Yuan G, Liu D, Shen Z, Zu N, Mu Y

Diabetes, obesity & metabolism11 Mar 2025Cited by 7 (Europe PMC)

PMID40069849 (opens in a new tab)PMCIDPMC11964988 (opens in a new tab)DOI10.1111/dom.16253 (opens in a new tab)PepBankPUB-40069849
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with overweight or obesity, semaglutide 2.4 mg reduced body weight more than placebo at Week 44 (estimated treatment difference -8.3%).

    In plain wordsIn Chinese adults with overweight or obesity, semaglutide 2.4 mg led to more weight loss than placebo over 44 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change from baseline to Week 44
    Study

    n = 300

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 44 weeksAs given in this study (human).

    Measurements

    Body weight change
    −11.8%
    semaglutide 2.4 mg
    Body weight change
    −3.5%
    placebo
    Estimated treatment difference
    −8.3%
    95% CI -10.2 to -6.4

    Source sentences

    Summary
    Estimated change in mean body weight from baseline to Week 44 was -11.8% with semaglutide 2.4 mg versus -3.5% with placebo (estimated treatment difference -8.3%; 95% confidence interval [CI] -10.2, -6.4; p < 0.0001).
    3 context sentences
    Summary · context
    The primary endpoints were percentage change in body weight from baseline to Week 44 and the proportion of participants who achieved ≥5% reduction in body weight from baseline.
    Summary · context
    In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced-calorie diet a…
    Summary · context
    Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with overweight or obesity, more participants on semaglutide 2.4 mg than on placebo lost at least 5% of body weight at Week 44 (85.4% vs 26.8%).

    In plain wordsIn Chinese adults with overweight or obesity, many more people on semaglutide 2.4 mg lost at least 5% of body weight than on placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with at least 5% body weight loss at Week 44
    Study

    n = 300

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 44 weeksAs given in this study (human).

    Measurements

    Participants with at least 5% weight loss
    85.4%
    semaglutide 2.4 mg
    Participants with at least 5% weight loss
    26.8%
    placebo
    Odds ratio
    16.1
    95% CI 8.4 to 30.9

    Source sentences

    Summary
    At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001.
    2 context sentences
    Summary · context
    In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced-calorie diet a…
    Summary · context
    Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo.
  3. 03HumanRandomized controlled trialSafety outcome

    In Chinese adults with overweight or obesity, adverse events were reported by 92.3% on semaglutide 2.4 mg and 82.9% on placebo.

    In plain wordsIn Chinese adults with overweight or obesity, side effects of any kind were reported by more people on semaglutide 2.4 mg than on placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseAny adverse event
    Study

    n = 300

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 44 weeksAs given in this study (human).

    Measurements

    Adverse events
    92.3%
    semaglutide 2.4 mg
    Adverse events
    82.9%
    placebo

    Source sentences

    Summary
    Adverse events were reported by 92.3% of semaglutide-treated participants and 82.9% of placebo-treated participants
    2 context sentences
    Summary · context
    In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced-calorie diet a…
    Summary · context
    Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo.
  4. 04HumanRandomized controlled trialSafety outcome

    In Chinese adults with overweight or obesity, gastrointestinal disorders were more frequent on semaglutide 2.4 mg (64.6%) than on placebo (33.3%).

    In plain wordsIn Chinese adults with overweight or obesity, stomach and gut side effects were more common on semaglutide 2.4 mg than on placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal disorders
    Study

    n = 300

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg once weekly · subcutaneous · 44 weeksAs given in this study (human).

    Measurements

    Gastrointestinal disorders
    64.6%
    semaglutide 2.4 mg, 126/195
    Gastrointestinal disorders
    33.3%
    placebo, 35/105

    Source sentences

    Summary
    gastrointestinal disorders (126/195, 64.6% vs. 35/105, 33.3%)
    2 context sentences
    Summary · context
    In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced-calorie diet a…
    Summary · context
    Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.